Researchers at Georgia State University have identified a promising antiviral drug candidate, GHP-88310, that could prevent measles from escalating into a full-blown outbreak. The drug, described in the journal Science Advances, is a broad-spectrum inhibitor of the viral polymerase, an enzyme critical for the virus's replication.
How GHP-88310 Works
Measles virus relies on its polymerase enzyme to copy its genetic material and reproduce. GHP-88310 blocks this enzyme, effectively halting viral replication. This mechanism is similar to some antiviral drugs used against other RNA viruses, but GHP-88310 appears to be highly specific to measles.
In laboratory tests, the drug showed potent activity against multiple strains of the measles virus, including those resistant to current treatments. The researchers noted that early administration could stop the virus from spreading within a community, reducing the risk of an outbreak.
Potential Impact on Public Health
Measles remains a major global health threat, especially in regions with low vaccination coverage. Although highly effective vaccines exist, outbreaks still occur due to vaccine hesitancy or limited access. An antiviral drug could serve as a crucial tool for outbreak control, particularly for unvaccinated individuals or those with weakened immune systems who cannot receive the vaccine.
“Current treatment options for measles are limited to supportive care and vitamin A supplementation,” said a researcher involved in the study. “An effective antiviral would fill a critical gap.”
Next Steps
The researchers plan to move the drug into animal studies and, if successful, clinical trials in humans. They emphasize that GHP-88310 is not intended to replace vaccination but to provide an additional layer of defense.
If proven safe and effective, the drug could be stockpiled for emergency use during outbreaks, potentially saving lives and preventing the costly public health measures required to contain measles.
